SCHEMBL6733052

SCHEMBL6733052

NS(=O)(=O)c1cc(F)c(-c2csc(=O)n2-c2cccnc2)cc1F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
MAPK14 Q16539 1/20 0.34
GAA P10253 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CA1 P00915 6/20 0.33
CA2 P00918 6/20 0.33
CA12 O43570 5/20 0.33
CA9 Q16790 5/20 0.33
CYP1A2 P05177 1/20 0.33
METAP2 P50579 1/20 0.33
HTT P42858 1/20 0.33
PTGS2 P35354 1/20 0.32
CA4 P22748 1/20 0.32
CA7 P43166 1/20 0.32
MAPT P10636 1/20 0.32
EP300 Q09472 1/20 0.32
KAT2B Q92831 1/20 0.32
DPP4 P27487 1/20 0.32
STAT3 P40763 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6730019 0.89 CYP11B1 (0.35) CYP11B1CYP11B2MAPK14GAAL3MBTL1
SCHEMBL6723429 0.85 CA1 (0.36) GAAL3MBTL1CA1CA2CA12
SCHEMBL6732538 0.84 CA2 (0.35) CA1CA2CA12CA9PTGS2
SCHEMBL6733028 0.83 PTGS2 (0.32) CYP11B1CYP11B2CA1CA2CA12
SCHEMBL6739469 0.83 PTGS2 (0.39) CA1CA2CA12CA9CYP1A2
SCHEMBL6735055 0.82 CA12 (0.37) CA1CA2CA12CA9PTGS2
SCHEMBL6734347 0.82 GSK3A (0.38) CA1CA2CA12CA9PTGS2
SCHEMBL6740641 0.81 PTGS2 (0.34) CA1CA2CA12CA9PTGS2
SCHEMBL6734979 0.81 PTGS2 (0.41) CYP11B1CYP11B2MAPK14CA1CA2
SCHEMBL6735831 0.81 CA12 (0.33) CA1CA2CA12CA9ILK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6699884-B2 ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. PHARMACIA CORPORATION 2004-03-02 US claimed
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-07-15 US disclosed
US-6699884-B2 ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. PHARMACIA CORPORATION 2004-03-02 US disclosed
US-6673818-B2 TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS ARTHRITIS, PAIN, FEVER AND CANCER PHARMACIA CORPORATION 2004-01-06 US disclosed
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-08-07 US disclosed
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-02-13 US disclosed
EP-1251126-A2 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation Pharmacia Corporation (US) 2002-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 CYP11B1 583/4885CYP11B2 573/4885MAPK14 2311/4885
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 CYP11B1 583/4885CYP11B2 573/4885MAPK14 2311/4885
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 CYP11B1 583/4885CYP11B2 573/4885MAPK14 2311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.